Taboo related to the Onchocerciasis causes Among Rural Population Obstructing Onchocerciasis Market Growth

Onchocerciasis is a term used to refer river blindness. It is caused due to biting of a parasitic worm and the consciousness of not treating the dieses could lead to serious complications. This parasitic worms are imparted within human skin through a particular black fly belonging to the samarium family. These worms start producing larvae once they enter human skin thus blocking human vision. The disease is mainly found among the people who leave close to moving streams and waterways of sub-Saharan range of Africa.

Get Sample Copy of this Report @

However, there is no prescribed diagnostic available for the diseases. At present doctors use biopsy on skin with regular saline and wait for the larva to come out. The method gives a short terms relax to the patient but it is does not produce any impact on patient. Another procedure that is used by medical professionals to treat this disease involves searching for the larvae in the eye as well as sensing bumps. Similar to first method, this method lacks in effectivity and results. There is no specific vaccine available against this disease mostly due to the lack of investments by the players. There are several reasons that has made this market quite speculative. One of them is inadequate awareness among people regarding the treatment of the dieses. Most of the patient still believes that dieses have no cure, hence they are not opting for the treatment of the diseases. This makes this market low profitable among the players.

Read Comprehensive Overview of Report @

However, government in several developing countries are making an effort to spread awareness among the patients and general public for the treatment of these disease. This is a prominent factor expected to drive the Onchocerciasis market in the coming few years.

Onchocerciasis Market Witnesses Rise in Diagnostic and Therapeutic Measures as R&D Activities Rise

Onchocerciasis, also referred to as river blindness, is a parasitic disease cause by the parasitic worm Onchocerca volvulus. The infectious disease is spread in humans through the bite of Simulium blackfly. Onchocerciasis is the second leading cause of blindness and can cause various skin diseases. Some of the key symptoms associated with onchocerciasis are partial or complete blindness, intense itching, skin rashes, skin depigmentation, nodules under the skin, saggy and drooping areas of skin, and lymph node inflammation.

Get Sample Copy of this Report @

The rising prevalence of the condition has led to a vast rise in R&D activities and the entry of several companies in the market in the recent years. The global market for onchocerciasis has been gaining traction owing to the vast developments observed in the field of diagnosis and treatment of the condition. The following treatments and diagnostic methods are available for the condition:

• Skin nip biopsy: The infectious larvae are identified with the aid of biopsy of the skin. A total of six snips are taken from different areas of the body and are put in physiologic solutions, i.e., normal saline to identify larvae.

• Antibody tests: Antibody tests are highly sensitive and are used to determine whether an individual had filarial infection. The most advantageous factor of the test is that it can identify the evidence of infection in the pre-patent stage of the disease.

• Slit-lamp examination: Infection in the eyes can be diagnosed with a slit-lamp examination of the eye in which the lesions caused are visible

• Ivermectin: Ivermectin destroys the larvae and prevents them from causing any damage. The treatment dose must be given every six months and it has been observed that ivermectin also reduces the occurrence of blindness and serious skin infections.

Read Comprehensive Overview of Report @

• Doxycycline: Doxycycline is used to destroy the Wolbachia bacteria that reside in adult parasitic worms. Due to the symbiotic relationship between Wolbachia and the worm, doxycycline may have effective activity against the adult worm.

Onchocerciasis Market Development of new medicines for diseases foretell 2025

Global Onchocerciasis Market: Snapshot

Onchocerciasis is caused by the infection of a specific type of parasitic worm inside the human body. The parasite is almost always transferred to the human body by black flies through biting. Global statistics show that onchocerciasis is the second-highest infection-based cause of blindness in the world, second only to trachoma. Common symptoms of onchocerciasis include bumps under the skin, excessive itching, and finally blindness. Studies show that a patient needs to be bitten for a large number of times to contract onchocerciasis.

There are, unfortunately, no vaccines present that can eradicate onchocerciasis. The most common form of cure for onchocerciasis is prevention, which is largely done using insect repellents or fully protective clothing near or inside rivers. Additional research and development is also being made towards the use of specialized insecticides that can help eliminate black flies, while from a medical perspective, the people living close to rivers can be given protective treatments twice a year. Common treatment includes the administration of a drug named ivermectin once every six to twelve months. However, it should be noted that ivermectin only destroys the larva without killing the adults. They can be weakened using doxycycline, an antibiotic that kills the bacteria associated with the adults. Additionally, surgical treatment may be recommended to patients in order to remove the lumps under their skins. The WHO lists onchocerciasis as a neglected tropical disease, and approximately 15.5 mn people are known to be suffering from it.

Request Sample Copy of the Report @

Global Onchocerciasis Market: Overview

Onchocerciasis, which is commonly known by the name of river blindness, is a disease that is caused by a parasitic worm named – Onchocerca volvulus. This infection disease is caused and spread in human beings through the bite of Simulium blackfly. This disease is considered as the second leading cause of blindness and can further lead to several other skin diseases. The rising awareness regarding this condition and the availability of therapeutics are expected to propel onchocerciasis market across the globe.

The research report provides an in-depth analysis of the global onchocerciasis market and throws light on the major factors that are expected to fuel the growth of the market in the near future. The key segmentation, opportunities, and limitations in the market have been highlighted to offer a clear understanding of the overall market.

Request TOC of the Report @

Global Onchocerciasis Market: Drivers and Restraints

A substantial rise in the number of cases of onchocerciasis, especially among American population is one of the vital factors fuelling the growth of the global market. In addition, the emergence of effective generic drugs for the treatment of onchocerciasis is expected to encourage the growth of the market in the next few years. The growing focus of governments in developing economies on the development of healthcare infrastructure and creating an awareness regarding the condition are further estimated to accelerate the growth of the market.

Furthermore, the rising disposable income among consumers, increasing government support, reimbursements policies, and favorable tax benefits are some of the other important factors that are projected to supplement the growth of the global onchocerciasis market throughout the forecast period. With these factors, the market is likely to register a healthy growth rate in the near future.

Read Comprehensive Overview of Report @

Global Onchocerciasis Market: Region-wise Outlook

The global market for onchocerciasis has been classified on the basis of geography to offer a strong understanding of the market. Among the key segments, Africa is projected to lead the global onchocerciasis market and hold a key share throughout the forecast period. The robust growth of this region can be attributed to the rising incidences of sustained and intense exposure to blackfly bites. In addition, the low awareness regarding the transmission of onchocerciasis disease is estimated to fuel the growth of the Africa market in the next few years.

Furthermore, Latin America and South America markets for onchocerciasis are anticipated to witness substantial growth throughout the forecast period. The untapped market in these regions and the lucrative opportunities for the prominent players are likely to accelerate the growth of the onchocerciasis market in the near future.

Key Players Mentioned in the Research Report are:

The leading players operating in the global onchocerciasis market are Merck & Co., Inc., Par Pharmaceutical Companies, Inc., Taj Pharmaceuticals Limited, Delta Pharma Ltd., Mayne Pharma Group, and Life Pharmaceutical Company. The increasing focus of key players on research and development activities and innovations is estimated to fuel the growth of the overall market throughout the forecast period. As per the study, the market is projected to witness stiff competition, owing to the rising number of players entering the global market.

Alarming Rise in Onchocerciasis to Accelerate Medicinal Intake

San Francisco, California, August 09, 2017: Growing support of governments to reimbursement policies is expected to have a positive impact on the market in the years to come, states TMR Research in a research report. The report is titled, “Onchocerciasis Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025.”

Onchocerciasis is caused by a particular kind infection of parasitic worm within the human body. The parasite is quite often exchanged to the human body by the biting of the black flies. Worldwide data demonstrate that onchocerciasis is the second-most infection-based for visual deficiency across the globe, second just to trachoma. Normal side effects of onchocerciasis incorporate skin bumps, excess itching, and lastly visual impairment. Studies demonstrate that a patient should be bitten for an extensive number of times to contract onchocerciasis.

There are, tragically, no immunizations currently that can destroy onchocerciasis. The most widely recognized type of cure for onchocerciasis is counteractive action, which is to a great extent done utilizing insect repellents or completely defensive apparel close or inside rivers. Further research and development work is additionally being made towards the utilization of particular bug sprays that can help dispose of black flies, while from a therapeutic point of view, the general population living near waterways can be given defensive medicines twice every year. Regular treatment incorporates the administration of a medication named ivermectin once every six to a year. In any case, it ought to be noticed that ivermectin just devastates the hatchling without slaughtering the grown-ups. They can be debilitated utilizing doxycycline, an anti-toxin that slaughters the microscopic organisms related with the grown-ups.

A considerable ascent in the quantity of instances of onchocerciasis, particularly among the American populace is one of the indispensable variables fuelling the development of the worldwide market. Also, the development of successful nonexclusive medications for the treatment of onchocerciasis is relied upon to bolster the progress of the market in the following couple of years. The developing concentration of governments in emerging economies on the improvement of medicinal services and spreading knowledge with respect to the condition are additionally assessed to quicken the growth of the market.

Region-wise, the market is expected to see a fruitful future in Africa owing to the growing incidences of the disease in the region and the need for medication as well. Moreover, South America and Latin America are also likely to emerge as potential regions for the market in the near future. Some of the core market players can be Life Pharmaceutical Company, Mayne Pharma Group, Delta Pharma Ltd., Taj Pharmaceuticals Limited, Par Pharmaceutical Companies, Inc., and Merck & Co., Inc., among others.

Click on the link below to request a sample copy of the report